Analysts Have Made A Financial Statement On BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Second-Quarter Report
BridgeBio Pharma Inc. (NASDAQ:BBIO) saw its shares rise 2.3% after its second-quarter report, with revenues of US$244m beating expectations but statutory losses widening to US$0.78 per share. Analysts have updated their forecasts, projecting US$1.01b in revenues for 2026, a 42% increase, while expecting losses …